Nuclea Biotechnologies offering $3M in stock sale

By Mass High Tech staff

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

Spin Transfer whips up $36M in first round [February 13, 2012]

Oxford Immunotec taps Altieri as CFO [February 13, 2012]

SeraCare selling to Linden for $82M [February 13, 2012]

Nuclea Biotechnologies LLC, a genomic research firm in Pittsfield, has sold about $1 million of a $3 million stock offering, according to a filing with the U.S. Securities and Exchange Commission.

As of the filing, eight unnamed buyers have partaken in the stock offering.

At the time of writing, Nuclea Biotechnologies officials were not available to confirm the offering nor discuss the plan for the additional funding.

The company aims to find biomarkers and gene or protein expression profiles that relate to cancer. Nuclea also researches therapeutics in the field of inflammation. The company maintains a biorepository and develops its tissue microarray technology, described as tissue samples that collect raw gene sequence information.

According to a release from the company last November, Nuclea moved the majority of its research and scientific positions to Worcester, where the company has a collaboration with Clark University.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.